Overall rank by patents
#22,560
of 50,000 tracked assignees
USPTO PatentsView assignee record - 12 granted patents across 5 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).
The verdict
According to USPTO PatentsView, Exsurco ranks #22,560 of 50,000 tracked US assignees by granted-patent volume, with 12 patents across 5 technology areas.
USPTO PatentsView assignee plate
Corpus R22560 · US Corporation #22,560 · 12 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: Excelerate Energy Limited Partnership (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Celagenex Research (… · near
34 score
Exsurco Medical · this assignee
34 score
Hermes-epitek · near
34 score
Nerudia · near
34 score
Tenacious Holdings · near
34 score
3D Lighting Innovati… · lowest
7 score
What this shows Exsurco's Innovation Score is 33.7/100 (top 55% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Exsurco Medical, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 66.7% of grants classified under A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). Peak complete grant year is 2018 (2 grants) versus a trough of 1 in 2015. By volume, Exsurco sits between Excelerate Energy Limited Partnership and FADU Inc..
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Excelerate Energy Limited Partnership
12 patents
Exordium Engineering LLC
12 patents
Exosect Limited
12 patents
Expander Energy, Inc.
12 patents
Extend Biosciences, Inc.
12 patents
FABER-CASTELL AG
12 patents
FACULTY PHYSICIANS AND SURGEONS OF LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE
12 patents
FADU Inc.
12 patents
Exsurco Medical, Inc.
12 patents
What this shows Exsurco holds 12 patents at rank #22,558, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #22,558 in granted patent volume.
Other assignees with the most granted patents in Exsurco's primary technology class.
Two PlainPatent-derived peer sets for Exsurco, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (34 here).
Exsurco's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
34 Top 55% higher than 45% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 8.3% |
| 2017 | 1 | 8.3% |
| 2018 | 2 | 16.7% |
| 2020 | 1 | 8.3% |
| 2021 | 2 | 16.7% |
| 2022 | 2 | 16.7% |
| 2023 | 1 | 8.3% |
| 2025partial year | 2 | 16.7% |
Top 5 of 5 technology areas
Overall rank by patents
#22,560
of 50,000 tracked assignees
33.7 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.